Key facts
- Aptadel Therapeutics’s last known valuation is $3.0M (Jan 2021).
- It has raised $4.5M.
- Notable investors include Barcelona Activa, Inc., Little Warrior Foundation, Newsight Tech Angels, Richi Entrepreneurs — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Aptadel Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aptadel Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aptadel Therapeutics
Operator of a biotech company intended for drug development for the treatment of cancer. The company offers a platform consisting of Aptamers linked to therapeutic agents, such as small RNA molecules or chemotherapeutic drugs, targeted to different tumors, enabling healthcare institutions to avoid side effects and improve therapy effectiveness.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2020
- Employees
- 9
- Website
- aptadeltx.com/
- Ownership
- Privately Held (backing)
Aptadel Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aptadel Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aptadel Therapeutics in its N-PORT filings yet. We sweep new filings monthly.